Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers

Can CDMOs keep up with the increasing demand for GLP-1 medications?

FDA’s program to speed up US manufacturing buildouts is short on detail

New Jersey remains hot life sciences hub despite macroeconomic, funding headwinds

Critical Timing: Hikma’s Billion-Dollar U.S. Investment

Editor’s (re)View: Is the biopharma industry’s glass half empty or half full?

Life sciences manufacturers overwhelmingly embrace smart tech: global survey

Flow state: The evolving shape of continuous manufacturing

[Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation

Editor’s (re)View: BMS, Merck, Roche see manufacturing flexibility as key to dealing with tariffs

Thermo Fisher opens cell therapy center, FDA cites Aurobindo site, Trump probes pharma imports ahead of tariffs [The good, the bad, the ugly]

Novartis to invest $23B in US sites, US urged to invest $15B in biotech counter to China, Trump warns of major pharma tariffs [The good, the bad, the ugly]

Cellares, Cabaletta validate automated CAR T production, FDA warns Aspen over sterility issues, rejects Hengrui, Elevar cancer combo again [The good, the bad, the ugly]

Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly]

Eli Lilly expands manufacturing to boost supply, FDA blocks imports from two Indian API makers, ICU Medical recalls potassium chloride injection bags over labeling error [The good, the bad, the ugly]

Novartis boosts Slovenia investment to $3.6B, Trump tariffs could unsettle biopharma FDI, FDA warns Global Calcium, blocks US imports [The good, the bad, the ugly]

FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly]

EU approves Novo-Catalent acquisition, CDMO National Resilience announces layoffs, FDA investigates blood cancer reports in gene therapy patients [The good, the bad, the ugly]

FDA approves Imkeldi oral solution, Alector axes workforce, Novartis announcnes layoffs [The good, the bad, the ugly]

FDA grants Regenxbio accelerated path for Duchenne, Neurogene reports death in Rett trial, Halozyme drops Evotec bid [The good, the bad, the ugly]